A phase 1/2 gene therapy trial demonstrated an 80% slowing of disease progression in Huntington's disease (HD) patients, as measured by the composite Unified Huntington's Disease Rating Scale.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.